Filing Flows

Filing Flows › Companies › Vivos Therapeutics › Cash flow

Vivos Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$3.6M in Q2 2026 · −$19.0M over twelve months

Operating cash flow−$3.1M
Capital spending−$416K
Free cash flow−$3.6M
Cash conversion cycle-74 days

Analysis

In Q2 2026, Vivos Therapeutics generated −$3.1M of operating cash flow and spent $416K on capital projects, leaving free cash flow of −$3.6M. That is $701K more than in Q2 2025 (−$4.3M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$17.1M; the largest uses were operating cash flow ($17.1M), capital spending ($1.9M), other investing ($50K); besides operations, cash came from other financing ($6.5M), shares issued ($5.9M); the cash balance fell by $2.6M.

Operating cash flow was −$3.1M against net income of −$5.5M. The largest differences: payables +$950K, accrued liabilities +$929K, depreciation & amortization +$510K.

Its cash conversion cycle was -74 days (receivables 28 + inventory 0 − payables 102): suppliers fund its working capital.

Free cash flow

Vivos Therapeutics: free cash flow by quarterVivos Therapeutics: free cash flow by quarter−$4.4MQ3 2024−$3.1MQ4 2024−$3.9MQ1 2025−$4.3MQ2 2025−$4.1MQ3 2025−$5.3MQ4 2025−$6.0MQ1 2026−$3.6MQ2 2026
Operating cash flow less capital spending.
Vivos Therapeutics: operating cash flow against capital spendingVivos Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$4.2M$192KQ3 2024−$2.9M$165KQ4 2024−$3.8M$122KQ1 2025−$3.5M$771KQ2 2025−$4.2M−$83KQ3 2025−$3.8M$1.5MQ4 2025−$6.0M$18KQ1 2026−$3.1M$416KQ2 2026
Latest (Q2 2026): Operating cash flow −$3.1M, Capital spending $416K.

Capital allocation, year by year

Vivos Therapeutics: where the cash came from (up) and went (down), by fiscal yearVivos Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$15.7MFY2021: Net borrowing −$25KFY2021: Shares issued $27.9MFY2021: Capital spending −$2.4MFY2021: Acquisitions −$225K$27.9MFY2021FY2022: Operating cash flow −$19.6MFY2022: Capital spending −$924KFY2022FY2023: Operating cash flow −$11.9MFY2023: Shares issued $4.0MFY2023: Capital spending −$803K$4.0MFY2023FY2024: Operating cash flow −$12.7MFY2024: Shares issued $7.8MFY2024: Capital spending −$568K$7.8MFY2024FY2025: Operating cash flow −$15.3MFY2025: Net borrowing $10.6MFY2025: Shares issued $5.6MFY2025: Capital spending −$2.3M$16.2MFY2025
Over these 5 years operating cash flow totalled −$75.2M; the largest uses were operating cash flow ($75.2M) and capital spending ($7.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$1.8M
Debt$582K
Net cash$1.2M
Due within a year$284K
Cash runway1 month

Vivos Therapeutics is burning cash: its operations consume cash, a free cash flow of −$19.0M a year at the current rate against $1.8M of cash and investments: a runway of about 1 month; $284K of debt also comes due within a year, which would need refinancing or new money before any new financing.

Vivos Therapeutics: debt maturities by year (FY2025)Vivos Therapeutics: debt maturities by year (FY2025)$284KYear 1$211KYear 2$162KYear 3$49KYear 4$31KYear 5$16KAfter year 5
Principal due in each year as disclosed in the annual report, against $1.8M of cash and investments now.

Where the cash came from and went

Vivos Therapeutics: sources (+) and uses (−) of cash, Q2 2026Vivos Therapeutics: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$3.1MNet borrowing (+) / repaid (−)$1.6MOther financing$1.3MCapital spending−$416KCash drawn (+) / kept (−)$336KShares issued$291K
Vivos Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Vivos Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$17.1MOther financing$6.5MShares issued$5.9MNet borrowing (+) / repaid (−)$4.1MCash drawn (+) / kept (−)$2.6MCapital spending−$1.9MOther investing−$50K

From profit to cash

Vivos Therapeutics: net income to operating cash flow, Q2 2026Vivos Therapeutics: net income to operating cash flow, Q2 2026Net income−$5.5MDepreciation & amortization$510KStock-based pay$50KReceivables$331KPayables$950KAccrued liabilities$929KDeferred revenue$88KPrepaid and other assets−$61KOther liabilities−$386KOperating cash flow−$3.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 202628—102-74
Q1 202629—79-50
Q4 202545—208-163
Q3 202526—62-37
Q2 202528—79-51
Q1 202517—69-52
Q4 202411—62-51
Q3 202410—94-83

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$3.1M−$416K$1.6M$291K$336K−$3.6M
Q1 2026−$6.0M−$18K$1.4M$342K−$81K−$6.0M
Q4 2025−$3.8M−$1.5M$1.4M$2.8M$1.1M−$5.3M
Q3 2025−$4.2M$83K−$417K$2.4M$1.3M−$4.1M
Q2 2025−$3.5M−$771K——−$2.1M−$4.3M
Q1 2025−$3.8M−$122K——$3.9M−$3.9M
Q4 2024−$2.9M−$165K—$3.5M$51K−$3.1M
Q3 2024−$4.2M−$192K——$592K−$4.4M

Vivos Therapeutics: income statement and cash flow

Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%. The chart follows the revenue to costs, profit and cash.

Vivos Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.